There are currently 30 active clinical trials seeking participants for Endometriosis research studies. The states with the highest number of trials for Endometriosis participants are Florida, Texas, California and Ohio.
Histologic Comparison of Ablative Techniques for Endometriosis
Recruiting
To our knowledge, no other human studies directly compare the effectiveness of the various ablative technologies. We set out to design a study to directly compare ablative energy sources and evaluate their ability to destroy native endometriosis tissue in humans.
Gender:
Female
Ages:
18 years and above
Trial Updated:
05/28/2024
Locations: Good Samaritan Hospital, Cincinnati, Ohio
Conditions: Endometriosis, Endometriosis-related Pain, Endometriosis Pelvic, Endometriosis; Peritoneum
Cardiovascular Disease Risk in Women With Endometriosis
Recruiting
To test the hypothesis that estrogen suppression impairs endothelial dysfunction in endometriosis.
Gender:
Female
Ages:
Between 18 years and 45 years
Trial Updated:
06/20/2024
Locations: John B Pierce Laboratory, New Haven, Connecticut
Conditions: Endometriosis
Study Of Oral Elagolix Tablets In Combination With Combined Oral Contraceptive Capsules/Tablets To Assess Dysmenorrhea Response In Adult Female Participants With Endometriosis And Associated Moderate To Severe Pain
Recruiting
Endometriosis is a painful disorder of the uterus affecting 6-10% of women of childbearing age. Endometriosis affects daily activities, social relationships, sexuality and sexual activity, and mental health. This study will evaluate how well elagolix in combination with combined oral contraceptives (COC) works within the body and/or how safe it is compared to placebo (does not contain treatment drug). This study will assess the dysmenorrhea (painful periods) response in participants with endomet... Read More
Gender:
Female
Ages:
Between 18 years and 49 years
Trial Updated:
06/19/2024
Locations: Pinnacle Research Group /ID# 217062, Anniston, Alabama +178 locations
Conditions: Endometriosis
A Study to Evaluate Pregnancy Outcomes in Females Treated With Oral Elagolix Tablets and Capsules
Recruiting
Orilissa is a drug approved for the management of moderate to severe pain associated with endometriosis. Oriahnn is approved for heavy menstrual bleeding due to uterine fibroids. Elagolix-containing products should not be taken by women who are pregnant or suspected to be pregnant but pregnancies are expected as the medicine does not completely stop ovulation and women may inadvertently continue taking Elagolix-containing products until their pregnancy is confirmed. This study will assess pregn... Read More
Gender:
Female
Ages:
All
Trial Updated:
06/14/2024
Locations: Iqvia /Id# 240918, Durham, North Carolina
Conditions: Endometriosis, Uterine Fibrioids
Feasibility of a Mindfulness Intervention for Endometriosis Surgery
Recruiting
Endometriosis is a common cause of pelvic pain in women which has been historically under-studied and under-diagnosed. The goal of this research is to pilot-test the feasibility and acceptability of a manualized, single-session brief mindfulness-based intervention (BMBI) among participants with endometriosis-related chronic pelvic pain (ECPP) who undergo surgical treatment, and gather preliminary data necessary for future studies assessing BMBI's impact on outcomes in surgically-treated ECPP. Th... Read More
Gender:
Female
Ages:
18 years and above
Trial Updated:
05/30/2024
Locations: Penn State Health, Hershey, Pennsylvania
Conditions: Endometriosis, Pain, Mindfulness
A Study to Investigate Efficacy and Safety of OG-6219 BID in 3 Dose Levels Compared With Placebo in Participants Aged 18 to 49 With Moderate to Severe Endometriosis-related Pain
Recruiting
The purpose of this global Phase 2 study is to determine the efficacy, safety, and tolerability of 3 dose levels of OG-6219 in pre-menopausal women between 18 and 49 years of age (inclusive), who have moderate to severe endometriosis-related pain.
Gender:
Female
Ages:
Between 18 years and 49 years
Trial Updated:
05/29/2024
Locations: Central Research Associates LLC dba Flourish Research, Birmingham, Alabama +108 locations
Conditions: Endometriosis
Cabergoline for the Treatment of Chronic Pain Due to Endometriosis
Recruiting
Endometriosis is dependent on angiogenesis (the sprouting of new blood vessels) for its growth and maintenance, but the side effects of currently approved angiogenesis inhibitors make these agents inappropriate for use in reproductive-age patients. This obstacle will be overcome by performing a randomized, double blind clinical trial aimed at repurposing an existing drug, cabergoline, as a safe, alternative angiogenesis inhibitor for adolescents and young women with endometriosis. This trial pro... Read More
Gender:
Female
Ages:
Between 15 years and 40 years
Trial Updated:
05/16/2024
Locations: Standford University, Palo Alto, California +4 locations
Conditions: Endometriosis
Pre-IVF Treatment With a GnRH Antagonist in Women With endometriosis_temp
Recruiting
A Phase 3 clinical trial of oral GnRH antagonist pre-treatment for women with endometriosis who are undergoing IVF, with a primary outcome of live birth rate. The investigators' central hypothesis is that in infertile woman with endometriosis undergoing in vitro fertilization-embryo transfer (IVF-ET), live birth rates will improve in those pretreated with GnRH antagonist compared to those not pretreated with GnRH antagonist.
Gender:
Female
Ages:
Between 18 years and 40 years
Trial Updated:
04/16/2024
Locations: University of Colorado Department of Obstetrics & Gynecology, Aurora, Colorado +4 locations
Conditions: Infertility, Endometriosis
At-Home Research Study for Patients With Autoimmune, Inflammatory, Genetic, Hematological, Infectious, Neurological, CNS, Oncological, Respiratory, Metabolic Conditions
Recruiting
We are the missing link in clinical trials, connecting patients and researchers seamlessly and conveniently using a mobile health platform to advance medical research. We make it easy for patients to contribute to research for medical conditions that matter most to them, regardless of their location or ability to travel.
Gender:
All
Ages:
Between 18 years and 100 years
Trial Updated:
04/15/2024
Locations: Sanguine Biosciences, Los Angeles, California
Conditions: All Diagnosed Health Conditions, ADD/ADHD, Alopecia Areata, Ankylosing Spondylitis, Asthma, Atopic Dermatitis Eczema, Beta Thalassemia, Bipolar Disorder, Breast Cancer, Celiac Disease, Cervical Cancer, Chronic Inflammatory Demyelinating Polyneuropathy, Chronic Kidney Diseases, Chronic Obstructive Pulmonary Disease, Colon Cancer, Colorectal Cancer, Crohn's Disease, Cystic Fibrosis, Depression, Diabetes Mellitus, Duchenne Muscular Dystrophy, Endometriosis, Epilepsy, Facioscapulohumeral Muscular Dystrophy, G6PD Deficiency, General Anxiety Disorder, Hepatitis B, Hereditary Hemorrhagic Telangiectasia, HIV/AIDS, Human Papilloma Virus, Huntington's Disease, Idiopathic Thrombocytopenic Purpura, Insomnia, Kidney Cancer, Leukemia, Lung Cancer, Lupus Nephritis, Lymphoma, Melanoma, Multiple Myeloma, Multiple Sclerosis, Myositis, Myotonic Dystrophy, Ovarian Cancer, Pancreatic Cancer, Parkinson's Disease, Polycystic Kidney Diseases, Prostate Cancer, Psoriasis, Psoriatic Arthritis, Rosacea, Scleroderma, Sickle Cell Anemia, Sickle Cell Trait, Sjogren's Syndrome, Skin Cancer, Spinal Muscular Atrophy, Systemic Lupus Erythematosus, Thrombotic Thrombocytopenic Purpura, Trisomy 21, Ulcerative Colitis
An AHEI Dietary Intervention to Reduce Pain in Women With Endometriosis
Recruiting
The investigators are conducting this study to examine if a healthy diet based on the Alternative Healthy Eating Index (AHEI) influences pain symptoms, quality of life, and inflammatory markers measured in blood samples in women with endometriosis who are currently experiencing pain symptoms.
Gender:
Female
Ages:
Between 18 years and 45 years
Trial Updated:
03/15/2024
Locations: Fred Hutchinson Cancer Research Center, Seattle, Washington
Conditions: Endometriosis
A Phase 3B Study to Evaluate Bone Mineral Density With Long-Term Use of Relugolix Combination Tablet in Women With Uterine Fibroids or Endometriosis
Recruiting
The purpose of this clinical trial to characterize changes in bone mineral density during continuous treatment with relugolix combination tablet for up to 48 months (4 years) and 1 year of post-treatment follow-up in premenopausal women with heavy menstrual bleeding associated with uterine leiomyomas (fibroids) or with moderate-to-severe pain associated with endometriosis.
Gender:
Female
Ages:
Between 18 years and 50 years
Trial Updated:
03/14/2024
Locations: Mobile, Mobile, Alabama +91 locations
Conditions: Uterine Fibroids, Endometriosis
Evaluation of Endometriosis With 18F-fluorofuranylnorprogesterone PET / MRI
Recruiting
Purpose: The aim of this study is to assess the sensitivity and specificity of FFNP PET/MRI for diagnosis of endometriosis. Participants: A total of 24 participants will be recruited from individuals with clinically suspected endometriosis. Procedures (methods): This is a prospective, one arm, single center study of 24 subjects with clinically suspected endometriosis to demonstrate FFNP PET-MRI's clinical utility for diagnosis of endometriosis.
Gender:
Female
Ages:
Between 18 years and 55 years
Trial Updated:
02/15/2024
Locations: University of North Carolina at Chapel Hill, Chapel Hill, North Carolina
Conditions: Endometriosis